Aurensanz-Clemente, EstherPérez Casares, ÁlexMuñoz, Juan PabloGarcía-Canadilla, PatriciaZuccarino, FlavioSánchez de Toledo, Joan2024-05-132024-05-132023Aurensanz-Clemente E, Pérez Casares Á, Muñoz JP, García-Canadilla P, Zuccarino F, Sanchez-de-Toledo J. Acute myocarditis with transient myocardial thickening in two oncologic patients treated with anti-GD2 immunotherapy. ESC Heart Fail. 2023 Jun;10(3):2090-3. DOI: 10.1002/ehf2.14330. Epub 2023 Mar 72055-5822http://hdl.handle.net/10230/60112Immunotherapy has considerably improved clinical outcomes in different types of cancers but has also been associated with the development of myocarditis, especially with that mediated by immune checkpoint inhibitors. To the best of our knowledge, these are the first cases of myocarditis after anti-GD2 immunotherapy reported to date. We present two cases of paediatric patients who, after anti-GD2 infusion, presented severe myocarditis with myocardial hypertrophy detected on echocardiography and confirmed with cardiac magnetic resonance imaging. An increase in myocardial T1 and extracellular volume of up to 30% was observed with heterogeneous intramyocardial late enhancement. Myocarditis after anti-GD2 immunotherapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.application/pdfeng© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any me-dium, provided the original work is properly cited and is not used for commercial purposes.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/ehf2.14330Cardiac magnetic resonance imagingCorticosteroidsImmunotherapyMyocarditisinfo:eu-repo/semantics/openAccess